AbbVie Inc (ABBV – Q3FY20) – Rinvoq and Skyrizi performance above expectation.

in , on December 31, 2020

The combination with Allergan, have created a stronger, more diverse company with robust cash flows, and multiple new growth vehicles for the long term.  The company now have the leading franchise which is demonstrating a strong V-shape recovery, as well as a highly attractive neuroscience portfolio that delivered double-digit growth on a comparable operational basis this quarter.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q3FY20 – Results
– Q3FY20 – Product Revenue
– Q3FY20 – R&D Update
– FY20 Guidance
– Conclusion
– GAAP to Non-GAAP reconciliation

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per Share Items and Key Ratios
– Key Balance Sheet and Cash Flow ratios
– P/E Band

Product Performance and Key Developments

– Ownership
– Competition
– Key Developments

Valuation and Consensus Performance

– Relative Valuation
– Analyst Recommendations

Market Price Performance

CrispIdea Coverage Chart

No of Pages : 52

Release Information

  • Released

    December 31, 2020

  • Last Updated

    December 31, 2020